PMID- 27527795
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20170605
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 57
IP  - 10
DP  - 2016 Oct
TI  - Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in 
      Israeli populations.
PG  - e205-e209
LID - 10.1111/epi.13498 [doi]
AB  - The human leukocyte antigen (HLA) alleles B*15:02 and A*31:01 have been 
      identified as predictive markers of adverse cutaneous effects of carbamazepine 
      and phenytoin in Asian and North European populations, respectively. Our aim was 
      to estimate the distribution of these alleles in Jewish and Arab populations in 
      Israel. The HLA-B*15:02 and HLA-A*31:01 carrier rate was estimated based on data 
      from the Hadassah Bone Marrow Registry. Data on Stevens-Johnson syndrome (SJS)- 
      and toxic epidermal necrolysis (TEN)-related hospitalizations were obtained from 
      the Israeli Ministry of Health (MOH) registries and from four Israeli medical 
      centers. Of 83,705 Jewish and Arab-Muslim donors, 81 individuals of known origin 
      carried the HLA-B*15:02. Among them, 66 were Jews of India-Cochin descent. Of the 
      Cochin Jewish donors, 12.7% were B*15:02 carriers. HLA-A*31:01 carrier incidence 
      among Arab and Jewish Israeli populations (3.5% and 2.2%, respectively) was 
      within the range reported in other countries. We did not identify SJS- or 
      TEN-related hospitalizations of Jews of Indian descent. Yet, this population 
      should be considered at greater risk for antiepileptic drug-induced SJS and TEN. 
      Until further data on actual risk are available, such patients should be typed 
      for HLA-B before treatment with carbamazepine or phenytoin.
CI  - Wiley Periodicals, Inc. (c) 2016 International League Against Epilepsy.
FAU - Israel, Shoshana
AU  - Israel S
AD  - Tissue Typing Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Maggio, Nicola
AU  - Maggio N
AD  - Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Ekstein, Dana
AU  - Ekstein D
AD  - Department of Neurology, Agnes Ginges Center for Human Neurogenetics, 
      Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Zaid, Huda
AU  - Zaid H
AD  - Institute for Drug Research, School of Pharmacy, The Hebrew University, 
      Jerusalem, Israel.
FAU - Firer, Maria
AU  - Firer M
AD  - Institute for Drug Research, School of Pharmacy, The Hebrew University, 
      Jerusalem, Israel.
FAU - Bederovsky, Yana
AU  - Bederovsky Y
AD  - Institute for Drug Research, School of Pharmacy, The Hebrew University, 
      Jerusalem, Israel.
FAU - Noyman, Iris
AU  - Noyman I
AD  - Department of Pediatric Neurology, Soroka Medical Center, Ben Gurion University 
      of the Negev, Beer Sheva, Israel.
FAU - Gandelman-Marton, Revital
AU  - Gandelman-Marton R
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel.
FAU - Blatt, Ilan
AU  - Blatt I
AD  - Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Brautbar, Chaim
AU  - Brautbar C
AD  - Tissue Typing Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Marom, Eli
AU  - Marom E
AD  - Department of Pharmacology, Israel Ministry of Health, Jerusalem, Israel.
FAU - Nahlieli Dil, Dorit
AU  - Nahlieli Dil D
AD  - Department of Pharmacology, Israel Ministry of Health, Jerusalem, Israel.
FAU - Berman, Erez
AU  - Berman E
AD  - Department of Pharmacology, Israel Ministry of Health, Jerusalem, Israel.
FAU - Sabag, David
AU  - Sabag D
AD  - Tissue Typing Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Ingber, Arieh
AU  - Ingber A
AD  - Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, 
      Israel.
FAU - Eyal, Sara
AU  - Eyal S
AD  - Institute for Drug Research, School of Pharmacy, The Hebrew University, 
      Jerusalem, Israel. sarae@ekmd.huji.ac.il.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160816
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Anticonvulsants/*adverse effects
MH  - Arabs
MH  - Drug Hypersensitivity/epidemiology/ethnology/*etiology/*genetics
MH  - Epilepsy/drug therapy/ethnology
MH  - Female
MH  - Genetic Predisposition to Disease/*genetics
MH  - HLA-A Antigens/*genetics
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Incidence
MH  - Israel/epidemiology/ethnology
MH  - Jews
MH  - Male
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Arab-Muslim
OT  - Carbamazepine
OT  - HLA-A*31:01
OT  - HLA-B*15:02
OT  - Jewish
OT  - Stevens-Johnson syndrome
EDAT- 2016/08/17 06:00
MHDA- 2017/06/06 06:00
CRDT- 2016/08/17 06:00
PHST- 2016/07/18 00:00 [accepted]
PHST- 2016/08/17 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
PHST- 2016/08/17 06:00 [entrez]
AID - 10.1111/epi.13498 [doi]
PST - ppublish
SO  - Epilepsia. 2016 Oct;57(10):e205-e209. doi: 10.1111/epi.13498. Epub 2016 Aug 16.